CD34 and acute myeloid leukemia: Notably, co-treatment with SNDX-50469 and adavosertib or panobinostat synergistically induced loss of viability in PD AML cells with mtNPM1 but not in the normal CD34+ progenitor cells (Fig. 6C, D and S6A, B).